Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHN NASDAQ:APLT NASDAQ:APRE NASDAQ:KNSA NASDAQ:PHAT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHNAchillion Pharmaceuticals$6.76$6.76$2.06▼$7.01$946.72M1.598.44 million shsN/AAPLTApplied Therapeutics$1.19-5.2%$0.61$0.30▼$10.62$170.65M2.073.46 million shs1.42 million shsAPREAprea Therapeutics$1.51+1.3%$1.54$1.37▼$5.01$8.80M1.339,796 shs40,438 shsKNSAKiniksa Pharmaceuticals International$38.77-0.2%$35.61$17.82▼$39.43$2.87B0.16632,363 shs317,907 shsPHATPhathom Pharmaceuticals$13.33-0.9%$11.56$2.21▼$19.50$948.45M0.431.67 million shs563,149 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHNAchillion Pharmaceuticals0.00%0.00%0.00%0.00%+754.41%APLTApplied Therapeutics+8.70%+16.82%+200.48%+166.01%-86.32%APREAprea Therapeutics-1.32%+4.05%-1.32%-10.78%-51.62%KNSAKiniksa Pharmaceuticals International+2.56%+1.44%+6.29%+34.74%+43.61%PHATPhathom Pharmaceuticals+7.60%+21.72%+17.16%+61.66%-14.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHNAchillion Pharmaceuticals$6.76$6.76$2.06▼$7.01$946.72M1.598.44 million shsN/AAPLTApplied Therapeutics$1.19-5.2%$0.61$0.30▼$10.62$170.65M2.073.46 million shs1.42 million shsAPREAprea Therapeutics$1.51+1.3%$1.54$1.37▼$5.01$8.80M1.339,796 shs40,438 shsKNSAKiniksa Pharmaceuticals International$38.77-0.2%$35.61$17.82▼$39.43$2.87B0.16632,363 shs317,907 shsPHATPhathom Pharmaceuticals$13.33-0.9%$11.56$2.21▼$19.50$948.45M0.431.67 million shs563,149 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHNAchillion Pharmaceuticals0.00%0.00%0.00%0.00%+754.41%APLTApplied Therapeutics+8.70%+16.82%+200.48%+166.01%-86.32%APREAprea Therapeutics-1.32%+4.05%-1.32%-10.78%-51.62%KNSAKiniksa Pharmaceuticals International+2.56%+1.44%+6.29%+34.74%+43.61%PHATPhathom Pharmaceuticals+7.60%+21.72%+17.16%+61.66%-14.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHNAchillion Pharmaceuticals 0.00N/AN/AN/AAPLTApplied Therapeutics 2.17Hold$4.13248.10% UpsideAPREAprea Therapeutics 2.33Hold$15.50926.49% UpsideKNSAKiniksa Pharmaceuticals International 2.78Moderate Buy$45.4317.19% UpsidePHATPhathom Pharmaceuticals 2.71Moderate Buy$17.5031.26% UpsideCurrent Analyst Ratings BreakdownLatest KNSA, APRE, ACHN, PHAT, and APLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025APLTApplied TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/13/2025KNSAKiniksa Pharmaceuticals InternationalWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$38.00 ➝ $44.0010/8/2025APREAprea TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025KNSAKiniksa Pharmaceuticals InternationalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025PHATPhathom PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025KNSAKiniksa Pharmaceuticals InternationalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/29/2025KNSAKiniksa Pharmaceuticals InternationalTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.009/27/2025APLTApplied TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025APREAprea TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025KNSAKiniksa Pharmaceuticals InternationalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025PHATPhathom PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHNAchillion PharmaceuticalsN/AN/AN/AN/A$1.92 per shareN/AAPLTApplied Therapeutics$121K1,410.37N/AN/A$0.49 per share2.42APREAprea TherapeuticsN/AN/AN/AN/A$3.55 per shareN/AKNSAKiniksa Pharmaceuticals International$529.33M5.43N/AN/A$6.60 per share5.87PHATPhathom Pharmaceuticals$114.04M8.29N/AN/A($3.71) per share-3.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHNAchillion Pharmaceuticals-$70.27M-$0.51N/AN/AN/AN/A-30.95%-29.09%N/AAPLTApplied Therapeutics-$105.62M-$0.45N/AN/AN/AN/A-354.24%-144.16%11/6/2025 (Estimated)APREAprea Therapeutics-$12.96M-$2.32N/AN/AN/A-1,645.01%-78.90%-62.67%11/6/2025 (Estimated)KNSAKiniksa Pharmaceuticals International-$43.19M$0.04969.27155.06N/A0.90%1.05%0.80%11/4/2025 (Estimated)PHATPhathom Pharmaceuticals-$334.33M-$4.73N/AN/AN/A-289.51%N/A-90.40%11/6/2025 (Estimated)Latest KNSA, APRE, ACHN, PHAT, and APLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025APLTApplied Therapeutics-$0.15N/AN/AN/AN/AN/A11/6/2025Q3 2025APREAprea Therapeutics-$0.11N/AN/AN/AN/AN/A11/6/2025Q3 2025PHATPhathom Pharmaceuticals-$0.30N/AN/AN/A$47.03 millionN/A11/4/2025Q3 2025KNSAKiniksa Pharmaceuticals International$0.31N/AN/AN/AN/AN/A8/13/2025Q2 2025APLTApplied Therapeutics-$0.17-$0.15+$0.02-$0.15$0.42 millionN/A8/12/2025Q2 2025APREAprea Therapeutics-$0.77-$0.53+$0.24-$0.53N/A$0.12 million7/29/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.18$0.23+$0.05$0.23$145.21 million$156.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHNAchillion PharmaceuticalsN/AN/AN/AN/AN/AAPLTApplied TherapeuticsN/AN/AN/AN/AN/AAPREAprea TherapeuticsN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHNAchillion Pharmaceuticals0.018.968.96APLTApplied TherapeuticsN/A1.941.94APREAprea TherapeuticsN/A5.345.34KNSAKiniksa Pharmaceuticals InternationalN/A3.573.16PHATPhathom PharmaceuticalsN/A2.382.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHNAchillion Pharmaceuticals79.42%APLTApplied Therapeutics98.31%APREAprea Therapeutics34.19%KNSAKiniksa Pharmaceuticals International53.95%PHATPhathom Pharmaceuticals99.01%Insider OwnershipCompanyInsider OwnershipACHNAchillion Pharmaceuticals4.58%APLTApplied Therapeutics1.60%APREAprea Therapeutics13.63%KNSAKiniksa Pharmaceuticals International53.48%PHATPhathom Pharmaceuticals23.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHNAchillion Pharmaceuticals56140.05 millionN/AOptionableAPLTApplied Therapeutics30144.01 million141.71 millionOptionableAPREAprea Therapeutics75.83 million5.03 millionNo DataKNSAKiniksa Pharmaceuticals International22074.11 million34.48 millionOptionablePHATPhathom Pharmaceuticals11070.94 million54.63 millionOptionableKNSA, APRE, ACHN, PHAT, and APLT HeadlinesRecent News About These CompaniesPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 7.8% - What's Next?October 14 at 2:36 PM | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 6.8% - Still a Buy?October 10, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Earns "Sell (D-)" Rating from Weiss RatingsOctober 10, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 7.8% - Here's What HappenedOctober 6, 2025 | marketbeat.comPhathom Pharma Appoints Sanjeev Narula as CFOOctober 6, 2025 | marketwatch.comPhathom appoints Sanjeev Narula as chief financial, business officerOctober 6, 2025 | msn.comPhathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business OfficerOctober 6, 2025 | globenewswire.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 5.5% - Still a Buy?September 30, 2025 | marketbeat.comPhathom Pharmaceuticals: A Study in Contrasts as Key Quarterly Report LoomsSeptember 26, 2025 | aktiencheck.deAPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Rating of "Buy" by BrokeragesSeptember 26, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) adds US$64m to market cap in the past 7 days, though investors from five years ago are still down 67%September 24, 2025 | finance.yahoo.comPhathom Pharmaceuticals Scores Relative Strength Rating Upgrade; Hits Key BenchmarkSeptember 23, 2025 | msn.comGoldman Sachs Group Inc. Cuts Stake in Phathom Pharmaceuticals, Inc. $PHATSeptember 22, 2025 | marketbeat.comPhathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's WhySeptember 18, 2025 | zacks.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 4.1% - Here's What HappenedSeptember 16, 2025 | marketbeat.comFDA targets Lilly, Novartis, BMS and more in deluge of marketing lettersSeptember 16, 2025 | fiercepharma.comFCheck out 15 DTC pharma ads that got flagged by FDASeptember 16, 2025 | mmm-online.comMFDA Letters Flag Oprah Video, Morgan Freeman Ad in CrackdownSeptember 16, 2025 | msn.comWall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?September 8, 2025 | zacks.comPhathom Pharmaceuticals: The IP Question Is Answered, But Can Management Deliver (Rating Upgrade)September 8, 2025 | seekingalpha.comPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKNSA, APRE, ACHN, PHAT, and APLT Company DescriptionsAchillion Pharmaceuticals NASDAQ:ACHNAchillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.Applied Therapeutics NASDAQ:APLT$1.18 -0.07 (-5.20%) As of 02:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Aprea Therapeutics NASDAQ:APRE$1.51 +0.02 (+1.34%) As of 02:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Kiniksa Pharmaceuticals International NASDAQ:KNSA$38.76 -0.10 (-0.24%) As of 02:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Phathom Pharmaceuticals NASDAQ:PHAT$13.33 -0.12 (-0.88%) As of 02:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
